- BriaCell (BCT) provided survival data from a clinical trial evaluating Bria-IMT and Incyte’s retifanlimab for the treatment of metastatic breast cancer
- The clinical data highlights survival benefits in a cohort with a life expectancy of merely months or weeks in some cases
- With patients continuing to enroll and remain on the treatment, more survival data will be disclosed in due course
- BriaCell Therapeutics is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer
- BriaCell Therapeutics Corp. (BCT) opened trading at C$10.00
BriaCell (BCT) provided survival data from a clinical trial evaluating Bria-IMT and Incyte’s retifanlimab for the treatment of metastatic breast cancer.
“This is working, and it’s working well. We had high hopes going into this clinical read-out, and the survival numbers have even exceeded our expectations. With 9 of 11 women still alive, this has a material impact on the patients and their loved ones, especially since some patients may have had only weeks or months to live prior to our treatment. This survival update bodes well for our upcoming pivotal trial since the FDA has agreed to survival benefits as the primary endpoint,” stated Dr. William V. Williams, BriaCell’s President and CEO.
Trial highlights:
- 9 of 11 (82 per cent) patients remain alive from 2021/2022 dosing, suggesting strong survival benefits
- 7 of 11 (64 per cent) patients showed either disease control or progression-free survival (PFS) benefits compared with their most recent prior therapy regimen suggesting clinical benefits
- A median PFS of 3.5 months compares favourably with other recent studies of patients with advanced disease
- The regimen remains well tolerated with no dose-limiting toxicities
The clinical data highlights survival benefits in a cohort with a life expectancy of merely months or weeks in some cases. Patients in this cohort had failed a median of 5 other treatments prior to enrolling in BriaCell’s study. Other reportable benefits, such as less pain and better quality of life, were also observed in these patients.
Nine additional patients have been screened/enrolled in the study, along with the 12 patients announced in December 2022. With patients continuing to enroll and remain on the treatment, more overall survival data will be disclosed at regular intervals.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell is conducting a Phase II clinical trial of Bria-IMT in metastatic advanced breast cancer (Fast Track designation from FDA). BriaCell is developing Bria-OTS, a personalized off-the-shelf immunotherapy for cancer-based on matching the patient’s HLA type. Enhanced cellular immunotherapies with enhanced potency are under development.
BriaCell Therapeutics Corp. (BCT) opened trading at C$10.00.
